Please select the option that best describes you:

Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?  

Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts?

Are there other toxicities of concern given anticipated long term use of therapy?

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Indiana University School of Medicine
Awareness is key for detecting clinically signific...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution